Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme

BACKGROUND: TAS-102 improves overall survival (OS) in patients with metastatic colorectal cancer (mCRC) refractory to standard treatments. However, predictive biomarkers of efficacy are currently lacking. PATIENTS AND METHODS: We treated a cohort of 43 chemorefractory mCRC patients treated with TAS-...

Descripción completa

Detalles Bibliográficos
Autores principales: Sforza, Vincenzo, Martinelli, Erika, Cardone, Claudia, Martini, Giulia, Napolitano, Stefania, Vitiello, Pietro Paolo, Vitale, Pasquale, Zanaletti, Nicoletta, Reginelli, Alfonso, Bisceglie, Maurizio Di, Latiano, Tiziana Pia, Bochicchio, Anna Maria, Cecere, Fabiana, Selvaggi, Francesco, Ciardiello, Fortunato, Troiani, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623320/
https://www.ncbi.nlm.nih.gov/pubmed/29018575
http://dx.doi.org/10.1136/esmoopen-2017-000229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623320/
https://www.ncbi.nlm.nih.gov/pubmed/29018575
http://dx.doi.org/10.1136/esmoopen-2017-000229

Ejemplares similares